Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly - GBI Research Reports

Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly

Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly - GBI Research Reports
Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
Published Oct 03, 2011
103 pages — Published Oct 03, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly, which provides key data, information and analysis of the major trends and issues affecting biomarkers in the drug discovery process. The report provides a comprehensive insight into the history of biomarkers, their uses and efficiency, as well as their limitations. The report also provides a detailed analysis of the biomarkers markets characterization in terms of its market size, segmentation by use of biomarkers in drug discovery, diagnostics and others and the major market drivers and barriers. The report also looks into the biomarkers pipeline as well as an analysis on the pipeline by indication, phase of development and geography of development. The report also provides a competitive landscape of the market that profiles key market players along with their brief business description, major products and major Mergers & Acquisitions (M&A) and partnership deals. The report also provides detailed analysis of major partnership and M&A deals that have taken place in the biomarkers market in the year 2010 and till May 2011 along with segmentation by deal type, geography and companies. Finally, the report provides the major conclusions about the biomarkers market

Scope

The report analyses the biomarkers in the drug discovery market along with the major forces driving the current market and the potential challenges that can restrain the growth. The scope of the report includes -
- An overview of biomarkers in the drug discovery process along with their use, efficiency and limitations.
- Annualized market data from 2002 and forecast forward to 2017, along with segmentation of the market into drug discovery, diagnostic and others.
- Key market drivers and restraints shaping the biomarkers market.
- Pipeline analysis of the biomarkers, along with segmentation by indication, phase and geography.
- Competitive landscape analysis with profiling of leading companies such as Quest Diagnostics, Vermillion, Amgen, Abbott and Roche.
- Analysis of partnership and M&A deals from 2010 till May 2011, along with segmentation by indication, deal type, geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop better strategies for biomarkers research by understanding the market dynamics of the biomarker drug discovery industry.
- Develop market-entry and market expansion strategies by identifying the key areas for high growth and high opportunities.
- Understand the factors shaping the biomarkers drug discovery market.
- Reinforce the R&D pipeline by identifying the key biomarker tests which can provide more accurate and early diagnosis of diseases.
- Identify the key players best positioned to take the advantage of the opportunities in the global biomarkers drug discovery market.
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

  
Source:
Document ID
GBIHC116MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents46
  List of Tables71
  List of Figures82
Biomarkers in Drug Discovery Introduction102
  Introduction101
  GBI Research Report Guidance111
Biomarkers in Drug Discovery Overview1223
  History of Biomarkers122
  Biomarker Classification141
    Biomarker Categories151
    Types of Biomarkers161
      Type 0 Markers161
      Type I Marker161
      Type II Biomarker161
    Example of Type 0, I and II Biomarker171
    Reasons Surrogate Endpoints Fail 172
  Biomarker Discovery and the Validation Process191
    Product Development Process from Discovery to Launch201
      Discovery201
      Development201
      Launch201
  General Application of Biomarkers211
    Biomarkers in Drug Discovery and Drug Development221
    Role of Biomarkers in the Drug Discovery Process231
    Application of Biomarkers in Disease Diagnosis and Prognosis232
    Potential Impact of Biomarkers on Disease States251
    Population Genetics Study261
    Environmental Health and Risk Assessment271
    Role of Biomarkers in Environmental Health and Risk Assessment281
      Health Risk Assessment281
      Clinical Diagnosis of Environmental Poisoning281
      Biological Screening and Monitoring281
    Toxicology Studies in Dietary Items or Nutraceuticals281
  Application of Biomarkers in Drug Discovery291
    Lead Identification and Optimization291
    Potential Role of Biomarkers in Lead Identification and Optimization301
    Target Validation301
    Toxicological Assay (Preclinical and Clinical)301
    Mechanism of Action311
    Monitor Therapy and Dose Response311
    Stratify Patient Population311
    Filing and Post Marketing Surveillance321
  Benefits of Biomarker Utilization321
    Disease Understanding321
    Project Prioritization through Early Attrition321
    Streamlining Clinical Trials321
    Reducing Cost of Drug Development331
    Speeding Drug Development331
    Avoiding Adverse Drug Reactions (ADR) and Rationalizing Dosing Regimen331
    Drug Repositioning331
  Challenges in Biomarker Utilization341
    Variability341
    Validity341
    Measurement Errors341
      Bias341
      Confounding341
      Cost341
      Acceptability341
Biomarkers in Drug Discovery Case Study352
  Cell Signaling Technology Enters Into Co-Marketing Agreement with Astellas Pharma351
    Definition351
    About Lung Cancer351
    Company Profile351
    Technology Used361
    Market Information361
    Advantages361
    Future Prospect361
Biomarkers in Drug Discovery Market Characterization3713
  Market Overview371
  Market Size and Forecasts371
    Global Biomarkers Market Size371
      Global Biomarkers Market Segmentation by Therapy Area381
    Global Biomarkers Drug Discovery Market391
    Global Biomarker s Molecular Diagnostics Market401
    Global Biomarkers Others Market411
    Global Biomarkers Market Segmentation421
    Drivers and Restraints431
    Drivers for the Global Biomarkers Market431
      Time Saving and Inexpensive - Biomarkers Cut Down Drug Discovery Cost By $100m and three-four Years for Each Drug431
      Better Regulatory Norms and Validation Procedures Encourage Growth of the Biomarker s Market441
      Broad Applications Extensive Range of Applications in Different Industrial Sectors Drives the Biomarkers Market towards Extensive Growth441
      Integration of Omics Increases the Scope of Application for Biomarkers in Other Technologies Leading to Growth441
      Advantageous Over Conventional Drug Discovery Methods Non-Invasive, Sensitive and Selective451
    Barriers for the Global Biomarkers Market461
      Awareness Gap Lack of Awareness about Intelligent and Novel Technological Advances Such as Biomarker Assays Restrain Market Growth461
      Diagnostic Uncertainty Complex Biomarker Based Techniques May Lead to False Positive Results Misleading the Clinical Trails461
      Funding Funding Organizations Require Strong Clinical Data and Validation to Provide Funds for the Research and Testing Phases of Biomarkers, Restraining Market Growth461
      Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector461
  Unmet Needs Biomarkers Fulfilling the Unmet Needs of Drug Discovery471
    High Attrition Rates481
    High Drug Discovery Cost481
    Time Consuming491
    Safety and Efficacy491
    Invasiveness, Selectivity and Sensitivity491
Biomarkers in Drug Discovery Trends Analysis506
  Regulatory Landscape (Current and Future)501
    Investigative/Exploratory Biomarker501
    Probable Valid Biomarker501
    Known Valid Biomarker501
    Regulatory Biomarker501
    Letter Of Intent to Propose Biomarker Qualification501
      Administrative Structure501
      Biomarker Qualification Overview501
      Overall Summaries of the Following (as appropriate):511
      Questions for FDA511
    Structure of Biomarker Qualification Briefing Document512
  Validated Biomarker532
  Regulatory Acceptance of Valid Biomarkers551
  Regulatory Guidance from the FDA, EMEA, and MHLW (Japan)551
Biomarkers in Drug Discovery Technology Adoptions563
  Unmet Need - Drug Discovery571
    Biomarkers Technology Exists to Fulfill Unmet Drug Discovery Needs571
  Increased Awareness among Pharmaceutical and Research Sector571
  Increasing Adoption Due to Wide Application571
  Biomarkers Future Drug Discovery Unmet Needs Fulfilled572
Biomarkers in Drug Discovery Competitive Landscape5923
  Key Biomarkers Players591
    Quest Diagnostics601
      SWOT Analysis611
    Life Technologies Corporation621
      SWOT Analysis631
    Vermillion641
      SWOT Analysis651
    BG Medicine661
      SWOT Analysis671
    Menarini681
      SWOT Analysis691
    Abbott701
      SWOT Analysis711
    Roche721
      SWOT Analysis731
    Genentech741
      SWOT Analysis751
    Affymetrix761
      SWOT Analysis771
    Amgen781
      SWOT Analysis791
  Global Biomarkers Market Geographic Landscape802
Biomarkers in Drug Discovery Pipeline Analysis826
  Pipeline Analysis821
    Biomarkers in Discovery Phase821
    Biomarkers in Phase I831
    Biomarkers in Phase II841
    Biomarkers in Phase III841
    Biomarkers in Phase IV841
    Pipeline Analysis by Phase851
    Pipeline Analysis Therapeutic Class861
    Pipeline Analysis by Geography871
Biomarkers in Drug Discovery Strategic Consolidations8812
  Strategic Consolidations by Deal Type881
  Mergers and Acquisitions892
    Mergers and Acquisitions by Geography911
    Major M&A Deals911
      David H. Murdock Research Institute Acquires the Immune Tolerance Institute911
      Health Diagnostic Laboratory Acquires Harris Scientific911
      Myriad Genetics Acquires Rules-based Medicine921
      CIT Safety Acquires LAB Research921
      Quest Diagnostics Completes Acquisition of Celera921
  Licensing Agreement Deals931
    Licensing Agreement Deals by Geography941
    Major Licensing Agreements951
      AVEO Pharmaceuticals Enters Into Licensing Agreement with Centocor Ortho Biotech951
      Prometheus Laboratories Signs Licensing Agreement with Bayer Schering Pharma951
      Dana-Farber Enters Into Licensing Agreement with Sanofi961
      OSI Pharmaceuticals Enters Into Licensing Agreement with AVEO Pharmaceuticals961
      KineMed Extends Licensing Agreement with Bristol-Myers Squibb961
  Partnership Deals971
    Major Partnership Deals981
      BG Medicine Enters Into Research Collaboration with Boston Scientific981
      MdxHealth Enters Into Co-Development Agreement with Newcastle University, Cancer Research Technology and Pfizer981
      Takeda Pharmaceutical Enters Into Co-Development Agreement with Kyoto University991
      Merck Serono Enters Into Research Agreement with Philochem991
Biomarkers in Drug Discovery Appendix1004
  Market Definitions1001
  Abbreviations1001
  Research Methodology1004
    Biomarkers in Drug Discovery- Overview1011
    Biomarkers in Drug Discovery- Case Study1011
    Biomarkers in Drug Discovery- Market Characterisation1011
    Biomarkers in Drug Discovery- Trends Analysis1011
    Biomarkers in Drug Discovery- Technology Adoptions1011
    Biomarkers in Drug Discovery- Competitive Landscape1011
    Biomarkers in Drug Discovery- Pipeline Analysis1011
    Biomarkers in Drug Discovery- Strategic Consolidations1021
    Coverage1021
    Secondary Research1021
    Primary Research1021
    Expert Panel Validation1031
  Contact Us1031
  Disclaimer1031
  Sources1031

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly" Oct 03, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Biomarkers-in-Drug-Discovery-Earlier-Usage-of-Biomarkers-in-Optimization-Stage-to-Reduce-Drug-Attrition-Rate-Significantly-2115-272>
  
APA:
GBI Research Reports. (2011). Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly Oct 03, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Biomarkers-in-Drug-Discovery-Earlier-Usage-of-Biomarkers-in-Optimization-Stage-to-Reduce-Drug-Attrition-Rate-Significantly-2115-272>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.